Combination human umbilical cord perivascular and endothelial colony forming cell therapy for ischemic cardiac injury.

IF 6.4 1区 医学 Q1 CELL & TISSUE ENGINEERING npj Regenerative Medicine Pub Date : 2023-08-25 DOI:10.1038/s41536-023-00321-3
Farwah Iqbal, Alexander Johnston, Brandon Wyse, Razieh Rabani, Poonam Mander, Banafshe Hoseini, Jun Wu, Ren-Ke Li, Andrée Gauthier-Fisher, Peter Szaraz, Clifford Librach
{"title":"Combination human umbilical cord perivascular and endothelial colony forming cell therapy for ischemic cardiac injury.","authors":"Farwah Iqbal, Alexander Johnston, Brandon Wyse, Razieh Rabani, Poonam Mander, Banafshe Hoseini, Jun Wu, Ren-Ke Li, Andrée Gauthier-Fisher, Peter Szaraz, Clifford Librach","doi":"10.1038/s41536-023-00321-3","DOIUrl":null,"url":null,"abstract":"<p><p>Cell-based therapeutics are promising interventions to repair ischemic cardiac tissue. However, no single cell type has yet been found to be both specialized and versatile enough to heal the heart. The synergistic effects of two regenerative cell types including endothelial colony forming cells (ECFC) and first-trimester human umbilical cord perivascular cells (FTM HUCPVC) with endothelial cell and pericyte properties respectively, on angiogenic and regenerative properties were tested in a rat model of myocardial infarction (MI), in vitro tube formation and Matrigel plug assay. The combination of FTM HUCPVCs and ECFCs synergistically reduced fibrosis and cardiomyocyte apoptosis, while promoting favorable cardiac remodeling and contractility. These effects were in part mediated by ANGPT2, PDGF-β, and VEGF-C. PDGF-β signaling-dependent synergistic effects on angiogenesis were also observed in vitro and in vivo. FTM HUCPVCs and ECFCs represent a cell combination therapy for promoting and sustaining vascularization following ischemic cardiac injury.</p>","PeriodicalId":54236,"journal":{"name":"npj Regenerative Medicine","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457300/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Regenerative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41536-023-00321-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 1

Abstract

Cell-based therapeutics are promising interventions to repair ischemic cardiac tissue. However, no single cell type has yet been found to be both specialized and versatile enough to heal the heart. The synergistic effects of two regenerative cell types including endothelial colony forming cells (ECFC) and first-trimester human umbilical cord perivascular cells (FTM HUCPVC) with endothelial cell and pericyte properties respectively, on angiogenic and regenerative properties were tested in a rat model of myocardial infarction (MI), in vitro tube formation and Matrigel plug assay. The combination of FTM HUCPVCs and ECFCs synergistically reduced fibrosis and cardiomyocyte apoptosis, while promoting favorable cardiac remodeling and contractility. These effects were in part mediated by ANGPT2, PDGF-β, and VEGF-C. PDGF-β signaling-dependent synergistic effects on angiogenesis were also observed in vitro and in vivo. FTM HUCPVCs and ECFCs represent a cell combination therapy for promoting and sustaining vascularization following ischemic cardiac injury.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脐带血管周围细胞与内皮细胞集落形成细胞联合治疗缺血性心脏损伤。
基于细胞的治疗方法是修复缺血心脏组织的有希望的干预措施。然而,目前还没有发现一种细胞类型既特化又万能,足以治愈心脏。采用大鼠心肌梗死(MI)模型、体外成管实验和Matrigel塞实验,研究了内皮集落形成细胞(ECFC)和孕早期脐带血管周围细胞(FTM HUCPVC)对血管生成和再生特性的协同作用。FTM HUCPVCs和ecfc联合使用可协同减少纤维化和心肌细胞凋亡,同时促进有利的心脏重塑和收缩。这些作用部分是由ANGPT2、PDGF-β和VEGF-C介导的。体外和体内也观察到PDGF-β信号依赖性对血管生成的协同作用。FTM HUCPVCs和ecfc代表了一种促进和维持缺血性心脏损伤后血管化的细胞联合疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
npj Regenerative Medicine
npj Regenerative Medicine Engineering-Biomedical Engineering
CiteScore
10.00
自引率
1.40%
发文量
71
审稿时长
12 weeks
期刊介绍: Regenerative Medicine, an innovative online-only journal, aims to advance research in the field of repairing and regenerating damaged tissues and organs within the human body. As a part of the prestigious Nature Partner Journals series and in partnership with ARMI, this high-quality, open access journal serves as a platform for scientists to explore effective therapies that harness the body's natural regenerative capabilities. With a focus on understanding the fundamental mechanisms of tissue damage and regeneration, npj Regenerative Medicine actively encourages studies that bridge the gap between basic research and clinical tissue repair strategies.
期刊最新文献
Systemic and local lipid adaptations underlie regeneration in Drosophila melanogaster and Ambystoma mexicanum. Regeneration-specific promoter switching facilitates Mest expression in the mouse digit tip to modulate neutrophil response. Immunomodulation by the combination of statin and matrix-bound nanovesicle enhances optic nerve regeneration. A latent Axin2+/Scx+ progenitor pool is the central organizer of tendon healing. A computational model reveals an early transient decrease in fiber cross-linking that unlocks adult regeneration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1